Oculis Holding AG Warrants
OCSAWStock
$4.57
Market Cap—
P/E—
Div yield—
Beta1.40
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-35.44%
Price vs S&P 500 (4W)23.69%
VGM Score17.36
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
OCSAWOculis Holding AG Warrants | — | — | F | $4.57 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Oculis Holding AG is a biopharmaceutical company developing targeted therapies for eye diseases and vision disorders. Its pipeline includes OCS-01 for diabetic macular edema, OCS-02 for dry eye disease, and OCS-05 for acute optic neuritis and other neuro-ophthalmologic conditions including glaucoma and diabetic retinopathy. The company employs topical and disease-modifying approaches to address significant unmet needs in ophthalmology.